Last reviewed: June 27, 2026
Last updated: June 27, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, originally developed to help people with type 2 diabetes manage blood sugar levels. As semaglutide has gained popularity for weight loss, many patients wonder whether the medication poses risks to kidney health—a legitimate concern given the prevalence of chronic kidney disease in people with obesity and diabetes.
How Semaglutide Works in Your Body
Semaglutide activates GLP-1 receptors throughout the body, including in the pancreas, stomach, and brain. This activation slows stomach emptying, increases feelings of fullness, and helps regulate appetite signals. The medication also improves how the body uses glucose and can lower blood pressure over time.
When semaglutide reduces body weight and improves blood sugar control, it often reduces stress on the kidneys indirectly. Extra weight and high blood sugar both contribute to kidney disease progression, so medications that address these conditions may actually support kidney function rather than harm it. However, the direct effects of semaglutide on kidney tissue remain an area of active research.
Clinical Evidence on Semaglutide and Kidney Function
Large-scale trials, including the SUSTAIN-6 study, have monitored kidney function in thousands of semaglutide users over several years. Results showed that semaglutide did not increase the risk of kidney disease progression in patients with type 2 diabetes, even those with pre-existing kidney disease. Some trials even suggested modest improvements in kidney filtration markers, possibly because weight loss and better blood sugar control reduce kidney stress.
It is important to note that semaglutide has never been shown to cause new kidney disease in healthy individuals or to worsen kidney function in patients without baseline kidney problems. The medication undergoes kidney filtration, so patients with severely reduced kidney function (glomerular filtration rate under 15) should discuss semaglutide with their healthcare provider. For most people using semaglutide for weight loss, kidney safety is supported by the available evidence.
Kidney Disease and Obesity: Why This Matters for Treatment
Obesity and chronic kidney disease often occur together. Excess weight increases blood pressure and inflammation, both of which accelerate kidney disease progression. People living with obesity are at higher risk for developing diabetes, which is the leading cause of kidney failure in the United States. Using semaglutide to achieve weight loss may help break this harmful cycle.
When semaglutide helps patients lose weight—an average of 10 to 15 percent of body weight in clinical trials—the reduced kidney workload can allow kidney function to stabilize or even improve slightly. This protective effect is especially important for people who have both obesity and early-stage kidney disease, a population that benefits from aggressive weight management alongside standard kidney disease care.
Personalized Kidney Safety Monitoring with PlexusDx
PlexusDx partners with patients to ensure semaglutide therapy aligns with their individual health profile, including kidney status. Before starting compounded semaglutide injection (available starting at $149 per month), PlexusDx-affiliated providers review baseline kidney function through simple blood tests that measure creatinine and estimate glomerular filtration rate. This baseline ensures that semaglutide remains a safe choice for your specific situation.
The Precision Peptide Genetic Test (a $99 add-on available after the first month of treatment) maps 14 metabolic pathways and 49 peptide-related genes, offering insight into how your body responds to GLP-1 therapy. While not a pharmacogenomic test, this peptide-pathway genetic analysis helps providers understand individual variations in appetite regulation, glucose metabolism, and weight loss response—information that may inform whether semaglutide alone or a combination therapy serves your health goals best. Patients with existing kidney disease can still use PlexusDx services; the key is transparent communication with your provider about your kidney function status.
What to Tell Your Doctor Before Starting Semaglutide
Before beginning semaglutide, inform your healthcare provider if you have any history of kidney disease, kidney stones, or reduced kidney function. Be prepared to share recent blood pressure readings and any medications you take for blood pressure or diabetes management. This information helps your provider assess whether semaglutide fits your clinical picture and whether dose adjustments or additional monitoring are needed.
If you are already taking semaglutide and notice changes in urination frequency, swelling in your legs or ankles, or persistent fatigue, contact your provider promptly. These symptoms are not necessarily caused by semaglutide but warrant investigation. PlexusDx-affiliated providers are trained to distinguish between side effects related to semaglutide itself (such as nausea or constipation) and signals that suggest a systemic issue requiring closer attention.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I use semaglutide if I already have kidney disease?
Many people with mild to moderate chronic kidney disease use semaglutide safely under medical supervision. However, if your glomerular filtration rate is severely reduced (below 15 mL/min/1.73m²), you should discuss semaglutide with your nephrologist or primary care provider. PlexusDx services are available to patients across the spectrum of kidney function, and your provider will help determine the safest approach for your situation.
Does semaglutide directly damage the kidneys?
No. Clinical evidence from major trials shows semaglutide does not cause kidney damage in patients with normal or mildly reduced kidney function. In fact, the weight loss and blood sugar improvement achieved by semaglutide often reduces stress on the kidneys. The medication is filtered by the kidneys but does not harm kidney tissue itself.
Will my kidney function be monitored while using semaglutide from PlexusDx?
Your PlexusDx-affiliated provider will request baseline kidney function tests before treatment begins. Ongoing monitoring depends on your individual health profile and whether you have pre-existing kidney disease. PlexusDx compounded semaglutide injection starts at $149 per month, and your provider will coordinate appropriate follow-up labs based on your specific clinical needs.
What side effects of semaglutide are common, and how do they relate to kidneys?
Common side effects—nausea, constipation, and decreased appetite—are not related to kidney problems. These effects usually improve over time as your body adjusts to the medication. Serious kidney-related side effects from semaglutide are extremely rare, and the available evidence suggests semaglutide is safe for kidney function in most users.
How does the PlexusDx Precision Peptide Genetic Test help with kidney safety?
The Precision Peptide Genetic Test ($99 add-on) analyzes genetic variants in pathways controlling appetite, glucose metabolism, and weight loss response. While not a kidney-specific test, understanding your genetic predispositions helps your provider choose the most effective GLP-1 therapy (semaglutide, tirzepatide, or a combination) and minimize the risk of unnecessary side effects that could complicate kidney health management.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Do You Lose Weight on Wegovy? Exploring Effective Strategies
Is Itching a Side Effect of Ozempic?